z-logo
Premium
Nail psoriasis: a combined treatment with 8% clobetasol nail lacquer and tacalcitol ointment
Author(s) -
Sánchez Regaña M,
Márquez Balbás G,
Umbert Millet P
Publication year - 2008
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.2008.02679.x
Subject(s) - medicine , dermatology , nail (fastener) , psoriasis , clobetasol propionate , nail matrix , nail plate , lacquer , materials science , metallurgy , chemistry , organic chemistry , coating
Background  Nail involvement is a common and distressing feature in the course of psoriasis. Although much progress has been made in the treatment of the disease, the presence of psoriasis in the nail continues to pose a challenge. In recent years, vitamin D3 analogs and a new formulation containing 8% clobetasol‐17‐propionate in a colourless nail lacquer vehicle have produced good results for the control of nail psoriasis. Objective  To determine the efficacy and safety of the combined treatment of 8% clobetasol‐17‐propionate in a lacquer vehicle and tacalcitol ointment in nail psoriasis. Methods  Fifteen patients with both nail bed and nail matrix psoriasis were included in the study. They were treated with a colourless nail lacquer containing 8% clobetasol‐17‐propionate applied at bedtime at the weekend, and with tacalcitol ointment under occlusion on the remaining days, for 6 months. Results  All 15 patients responded well to treatment. The therapeutic effect was very fast and directly related to the length of therapy. All nail alterations, including nail pain, were reduced, and the modified target Nail Psoriasis Severity Index fell by an average of 78% compared to baseline levels (±59.6, P  < 0.0001). Conclusions  Combined treatment with tacalcitol ointment and 8% clobetasol‐17‐propionate in a nail lacquer is a safe, effective treatment for nail bed and nail matrix psoriasis.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here